<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164790">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01876797</url>
  </required_header>
  <id_info>
    <org_study_id>Hyeong-Seok Lim</org_study_id>
    <nct_id>NCT01876797</nct_id>
  </id_info>
  <brief_title>PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males</brief_title>
  <official_title>A Single Dose, Open-label, One Sequence, 2-period, Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to characterize the pharmacokinetic and pharmacodynamics of ticagrelor and
      prasugrel in healthy Korean male subjects.

      The study is open label, one sequence, crossover design. In period 1, a single oral dose of
      180 mg ticagrelor will be administrated. After at least 7 days washout period, in period 2,
      a single oral dose of 60 mg prasugrel will be administrated.

      After dosing each period, blood sampling for PK and PD assessment will be conducted.

        1. Blood Sampling Times

             1. PK :predose,10 min,15 min,25 min, 0.5,1,1.5,2,2.5,4,6,8,12 and 24h post-dose

             2. PD :predose,15 min,0.5,1,2,4,6,8,12 and 24h post-dose

        2. Bioanalysis

             1. plasma Ticagrelor

             2. plasma AR-C124910XX (active metabolite of ticagrelor)

             3. plasma R-95913 (inactive metabolite of prasugrel)

             4. plasma R-13727 (active metabolite of prasugrel)

        3. Platelet Aggregation Test using turbidometric Method Maximal Platelet Aggregation(MPA)

        4. PK-PD Modeling analysis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>plasma ticagrelor parent,AR-C124910XX,R-95913 and R-13727</measure>
    <time_frame>0,10 min,15 min,25 min,0.5h,1h,1.5h,2h,2.5h,4h,6h,8h,12h and 24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>4 mL of blood will be drawn per each collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Platelet Aggregation(MPA)</measure>
    <time_frame>0,15 min,0.5 min, 1h,2h,4h,8h and 24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>platelet aggregation will be tested using light transmission aggregometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse event monitoring</measure>
    <time_frame>up to 1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>all adverse event will be collected</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ticagrelor-prasugrel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor/prasugrel</intervention_name>
    <arm_group_label>ticagrelor-prasugrel</arm_group_label>
    <other_name>ticagrelor :2 tablets of Brilinta® 90 mg</other_name>
    <other_name>prasugrel : 6 tablets of Effient® 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male aged 19 - 45 years at screening visit

          2. body weight at least 60 kg at screening visit

          3. body mass index 18 - 30 kg/m2

          4. SBP 90 - 149 mmHg and DBP 60 - 99 mmHg and pulse rate(beat per minute) 45 - 100 at
             screening visit

        Exclusion Criteria:

          1. any history of or having any clinically significant abnormalities

          2. any gastrointestinal disorder having impact on absorption of study drug

          3. any history of hypersensitivity of ticagrelor or prasugrel or compounds related study
             drugs

          4. any history of taking original medicines within 30 days before dosing or history of
             taking prescribed drug within 14 days before dosing or history       of taking OTC
             drug within 7 days before dosing

          5. any history of taking other study drug within 60 days before dosing

          6. any history of whole blood transfusion within 60 days before dosing or history of
             blood elements transfusion or history of  heaving been transfused within 30 days
             before 30 days

          7. any history of taking metabolic inducer or inhibitor

          8. overuse (caffeine: &gt; 5 units/day , alcohol: &gt; 21 units /week, smoking: &gt; 10
             cigarettes/day)

          9. positive serology testy(Hbs antigen, HIV, Hepatitis C virus, Syphilis)

         10. any abnormality in clinical laboratory tests result or any ECG finding considered to
             be inadequate by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Seok Lim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>June 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeong-Seok Lim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
